Sugammadex is a polar molecule, specifically a gamma cyclodextrin, that completely reverses neuromuscular blockade of rocuronium or vecuronium by forming a 1:1 ratio complex. This prevents the non-depolarizing neuromuscular blocking agent from binding to the nicotinic receptor located on at the neuromuscular junction. Important dosing considerations should be noted especially regarding patients that have altered blood brain barrier (BBB) permeability. For instance, this consideration is applicable to many neurodegenerative diseases such as Parkinson’s Disease and cranial traumas. The hydrophilic structure of the Sugammadex molecule when exposed to increased BBB permeability will translocate and possibly lead to precipitated cellular apoptosis. In patients prone to early neuronal deterioration by various pathological processes, the consideration of both calculated dosing and patient population is vital and perhaps necessary in prevention of further detrimental intracellular neuronal effects.